HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis.

MLA

Garcia Pavia, P., et al. “HELIOS-A: 18-Month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis.” Archives of Cardiovascular Diseases Supplements, vol. 15, no. 1, Jan. 2023, pp. 31–32. EBSCOhost, https://doi.org/10.1016/j.acvdsp.2022.10.056.

APA

Garcia Pavia, P., Gillmore, J. D., Kale, P., Berk, J. L., Maurer, M. S., Conceição, I., Dicarli, M., Solomon, S., Chen, C., Arum, S., Vest, J., Grogan, M., & Hababou, C. (2023). HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis. Archives of Cardiovascular Diseases Supplements, 15(1), 31–32. https://doi.org/10.1016/j.acvdsp.2022.10.056

Chicago

Garcia Pavia, P., J.D. Gillmore, P. Kale, J.L. Berk, M.S. Maurer, I. Conceição, M. Dicarli, et al. 2023. “HELIOS-A: 18-Month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis.” Archives of Cardiovascular Diseases Supplements 15 (1): 31–32. doi:10.1016/j.acvdsp.2022.10.056.